Keytruda (Pembrolizumab)

Keytruda (Pembrolizumab)

Context

Investigations have recently uncovered a sophisticated counterfeit market for Keytruda in India. The rise of these fakes is attributed to high drug prices and security breaches at the hospital level, posing a grave risk to patients seeking life-saving cancer treatment.

About Keytruda

Definition: Keytruda is the brand name for Pembrolizumab, a groundbreaking immunotherapy drug. It is classified as a checkpoint inhibitor, designed to treat various advanced and aggressive cancers by leveraging the body's own defenses.

The Manufacturer: The drug is developed and manufactured by Merck & Co. (operating as MSD outside the U.S. and Canada).

Primary Objective: Keytruda aims to "release the brakes" on the immune system. It prevents cancer cells from using biological "cloaking" techniques to hide from the body's T-cells, enabling the immune system to recognize and eliminate the tumor.

Key Features and Mechanism

• Mechanism of Action: It targets and binds to the PD-1 (Programmed Death-1) protein on the surface of T-cells. By blocking the interaction between PD-1 and the PD-L1 ligands on cancer cells, it prevents the "off-switch" signal that cancer cells use to evade detection.
• Monoclonal Antibody: As a laboratory-made molecule, it is engineered to specifically restore or enhance the immune system's natural attack on malignant cells.
• Targeted Therapy: Unlike traditional chemotherapy, which can be indiscriminate in killing cells, Keytruda is highly selective. This targeted approach generally spares healthy tissue, potentially reducing certain systemic side effects.
• Broad Spectrum: Initially approved for Melanoma (skin cancer) in 2014, its use has expanded to include lung, cervical, renal cell, and triple-negative breast cancers.

Patient Access in India

• High Cost: Keytruda remains one of the most expensive medications on the market, which has unfortunately fueled the demand for cheaper, illicit counterfeits.
• Support Schemes: Merck operates a Patient Access Programme in India (e.g., a "buy 5, get 30 free" model) aimed at patients with an annual income below ₹25 lakh or those with specific insurance constraints to help mitigate the financial burden.

Implications for India’s Healthcare

• The Cancer Burden: With India's cancer cases expected to rise by approximately 74% by 2045, the availability of advanced biologics like Keytruda is vital for public health.
• Access Inequality: The high price point creates a significant disparity in care. While wealthy patients can afford genuine treatment, others are left vulnerable to predatory counterfeiters selling ineffective or harmful fakes.
• Regulatory Challenge: The recent investigations highlight the urgent need for a more transparent supply chain and stricter "track and trace" mechanisms for high-value oncology drugs in Indian hospitals.

Conclusion

Keytruda represents the pinnacle of modern oncology, turning the immune system into a powerful weapon against cancer. However, its success in India is currently overshadowed by the challenges of affordability and authenticity. Ensuring that patients receive genuine, life-saving medication remains a critical hurdle for India's healthcare regulatory bodies.